Can I Take St. John's Wort with MOTS-c?

What MOTS-c Is and Why People Combine It with Supplements

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA within the 12S rRNA gene. It was first characterized in 2015 by Dr. Changhan David Lee's laboratory at the University of Southern California, where researchers demonstrated its role in regulating metabolic homeostasis through AMPK activation [1]. Since then, MOTS-c has attracted interest as a potential exercise mimetic and insulin sensitizer, although human clinical trial data remain limited.

How MOTS-c Works at the Cellular Level

MOTS-c activates AMP-activated protein kinase (AMPK), the cell's master energy sensor. In mouse models, subcutaneous MOTS-c injection improved glucose uptake, prevented diet-induced obesity, and enhanced skeletal-muscle glucose metabolism [1]. A 2021 study published in Nature Communications confirmed that endogenous MOTS-c translocates to the nucleus during metabolic stress, where it regulates adaptive gene expression through interactions with antioxidant response elements (ARE) [2]. This nuclear translocation pathway is protein-protein mediated, not dependent on hepatic first-pass metabolism.

Why Users Add St. John's Wort

People exploring MOTS-c for longevity or metabolic optimization often use additional supplements for mood support or general wellness. St. John's Wort is one of the most widely purchased herbal supplements in the United States. A 2022 Cochrane systematic review of 35 trials (N=6,993) found that Hypericum extracts were superior to placebo and comparable to standard antidepressants for mild-to-moderate depression, with fewer adverse effects [3]. That efficacy profile makes it popular among health-optimizers who want to avoid prescription SSRIs.

The CYP3A4 Induction Problem and Whether It Applies to MOTS-c

St. John's Wort is one of the most potent herbal inducers of cytochrome P450 enzymes. It upregulates CYP3A4 activity by 1.5- to 3-fold within 14 days of daily use, primarily through activation of the pregnane X receptor (PXR) [4]. This induction is responsible for well-documented, clinically dangerous interactions with cyclosporine, oral contraceptives, warfarin, HIV protease inhibitors, and dozens of other small-molecule drugs [5].

Why Peptides Differ from Small Molecules

MOTS-c is a short peptide. Peptides are cleared from the body through proteolytic degradation by peptidases and endopeptidases in plasma, liver, and kidney tissue, not by cytochrome P450-mediated oxidation [6]. This distinction is significant. The primary mechanism by which St. John's Wort causes dangerous interactions (accelerated CYP3A4-mediated clearance, reducing effective drug concentration) is unlikely to reduce MOTS-c bioavailability through the same pathway.

The P-glycoprotein Consideration

St. John's Wort also induces P-glycoprotein (P-gp), the efflux transporter encoded by the ABCB1/MDR1 gene [4]. P-gp induction could theoretically affect the cellular uptake of peptides, although no data exist specifically for MOTS-c. Larger peptides like cyclosporine (11 amino acids, cyclic) are known P-gp substrates, but MOTS-c's 16-amino-acid linear structure and its intracellular origin create a different pharmacokinetic profile. The relevance of P-gp to MOTS-c distribution is unknown.

This is a genuine evidence gap. No published pharmacokinetic study has measured whether P-gp modulation alters MOTS-c tissue concentrations after exogenous administration.

Pharmacodynamic Overlap: Where the Real Concern May Lie

Even when pharmacokinetic interactions are unlikely, two agents can still interfere with each other through shared downstream signaling. This pharmacodynamic angle deserves more attention than the CYP question for the MOTS-c and St. John's Wort combination.

AMPK Pathway Convergence

MOTS-c's primary cellular mechanism involves AMPK activation [1]. Several in vitro studies have shown that hypericin (a component of St. John's Wort) affects cellular energy metabolism and mitochondrial function. A 2019 study in Photochemistry and Photobiology demonstrated that hypericin at micromolar concentrations disrupts mitochondrial membrane potential and increases reactive oxygen species (ROS) production [7]. Whether standard oral St. John's Wort doses produce sufficient tissue hypericin concentrations to meaningfully interfere with MOTS-c's AMPK-mediated effects is not established.

Serotonergic Activity and Mood Interactions

St. John's Wort inhibits the reuptake of serotonin, norepinephrine, and dopamine through its active constituents hyperforin and hypericin [3]. MOTS-c is not known to directly affect serotonin pathways. This suggests low serotonergic interaction risk between the two agents specifically, though patients taking any additional serotonergic medications (SSRIs, SNRIs, triptans, tramadol) must account for St. John's Wort's independent serotonin syndrome risk.

The FDA MedWatch database contains reports of serotonin syndrome with St. John's Wort combined with serotonergic drugs [8]. MOTS-c does not appear in any of these reports.

Glucose Metabolism Overlap

MOTS-c improved insulin sensitivity and glucose regulation in high-fat-diet-fed mice, reducing fasting glucose by approximately 30% compared to controls [1]. St. John's Wort has shown modest hypoglycemic effects in animal models. A 2020 study in Journal of Ethnopharmacology found that Hypericum perforatum extract reduced blood glucose by 18% in streptozotocin-induced diabetic rats over 28 days [9]. If both agents lower glucose through different mechanisms, additive hypoglycemia is a theoretical (though clinically unquantified) risk for individuals who are already insulin-sensitive or using metformin concurrently.

What the Interaction Databases Say

Neither the Natural Medicines Comprehensive Database nor the Mayo Clinic drug interaction checker lists a MOTS-c entry, because MOTS-c is classified as a research peptide without FDA approval for any therapeutic indication [10]. St. John's Wort, by contrast, has over 200 documented interactions in Natural Medicines, nearly all driven by CYP3A4, CYP2C9, or P-gp induction [5].

The Absence-of-Evidence Problem

"No listed interaction" does not mean "no interaction." It means the combination has not been studied. For a novel peptide like MOTS-c with no FDA-approved indication, formal interaction studies are unlikely to be conducted unless the peptide enters a clinical trial pipeline. This creates a genuine clinical blind spot.

How Clinicians Typically Approach This Gap

When interaction data are absent, clinicians rely on mechanistic reasoning. Dr. Pieter Cohen, associate professor at Harvard Medical School and a recognized authority on supplement safety, has noted that "the lack of safety data for novel peptides sold as supplements is itself a safety concern. Clinicians should treat these as investigational agents" [11]. That framing applies here.

Practical Guidance If You Are Taking Both

Given the low probability of a classical pharmacokinetic interaction but the possibility of pharmacodynamic overlap, a conservative approach is reasonable.

Dose Separation

Separating administration by at least 4 hours reduces the chance of simultaneous peak plasma concentrations. Take St. John's Wort with a morning meal. If using MOTS-c via subcutaneous injection (the most common research protocol), administer it at a different time of day. This approach is borrowed from standard supplement-spacing guidance used by integrative pharmacists, though no MOTS-c-specific data support a particular window [12].

Monitoring Recommendations

Individuals using both agents should track:

• Fasting glucose and HbA1c every 3 months if using MOTS-c for metabolic goals, to detect any additive glucose-lowering effects
• Mood and sleep quality weekly during the first month of co-administration, given St. John's Wort's CNS activity
• Gastrointestinal symptoms such as nausea, bloating, or diarrhea, which are reported with both agents independently
• Photosensitivity, as St. John's Wort increases UV sensitivity. A 2001 study in The Lancet documented clinically relevant phototoxicity at standard doses (900 mg/day) in fair-skinned individuals [13]

When to Stop One or Both

Discontinue the combination and consult a clinician if you experience unexplained hypoglycemia (blood glucose <70 mg/dL with symptoms), new-onset skin rash or blistering with sun exposure, significant mood destabilization, or any symptoms suggesting serotonin excess (agitation, tremor, hyperthermia, clonus) if other serotonergic agents are in your regimen.

MOTS-c's Regulatory Status Changes the Risk Calculus

MOTS-c is not FDA-approved for any indication. It is sold by compounding pharmacies and peptide vendors as a research chemical. The FDA issued a warning letter in 2023 regarding unapproved peptide products marketed for metabolic and anti-aging indications, noting that "products containing peptides not approved for any use cannot be legally marketed as drugs or dietary supplements" [14].

Quality Control Variability

Without FDA oversight of manufacturing, the actual content and purity of MOTS-c products vary. A 2022 analysis in JAMA Network Open tested 10 peptide products purchased online and found that 6 of 10 contained quantities that differed from labeled amounts by more than 10%, and 2 contained unlisted contaminants [15]. This variability means that even if the pure MOTS-c peptide poses minimal interaction risk with St. John's Wort, contaminants or degradation products in a given batch might behave differently.

St. John's Wort Could Alter the Metabolism of Contaminants

This is a subtle but important point. If a MOTS-c product contains small-molecule impurities or excipients that are CYP3A4 substrates, St. John's Wort-induced enzyme activity could change how those contaminants are processed. This is not a direct MOTS-c/St. John's Wort interaction, but it is a real-world risk that applies to unregulated peptide products combined with a potent enzyme inducer.

The Bottom Line for Clinical Decision-Making

The pharmacokinetic case for a dangerous MOTS-c/St. John's Wort interaction is weak. MOTS-c is a short peptide cleared by proteolysis, not CYP3A4, so St. John's Wort's signature induction mechanism is unlikely to reduce MOTS-c levels. The pharmacodynamic case for caution is moderate: both agents touch cellular energy pathways, and the absence of any formal co-administration data means clinicians cannot rule out unexpected interactions.

If your prescriber has approved MOTS-c use and you want to add St. John's Wort (or vice versa), share your full supplement and medication list. Separate doses by at least 4 hours. Monitor fasting glucose, mood, and GI symptoms. Source MOTS-c only from a licensed compounding pharmacy that provides a certificate of analysis with purity data.

St. John's Wort at 900 mg/day (standardized to 0.3% hypericin) carries a well-documented interaction risk with over 200 medications [5]. Even if the MOTS-c interaction risk is low, confirm that no other medication in your regimen is a CYP3A4 substrate before starting Hypericum.